Archford Capital Strategies LLC Invests $545,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Archford Capital Strategies LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,019 shares of the biopharmaceutical company's stock, valued at approximately $545,000.

Several other large investors have also recently bought and sold shares of the business. Investment Management Corp of Ontario raised its position in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after acquiring an additional 40 shares in the last quarter. Nixon Peabody Trust Co. raised its position in Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock worth $540,000 after acquiring an additional 43 shares in the last quarter. Brevan Howard Capital Management LP raised its position in Alnylam Pharmaceuticals by 3.4% in the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 44 shares in the last quarter. IFP Advisors Inc raised its position in Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares in the last quarter. Finally, Nwam LLC raised its position in Alnylam Pharmaceuticals by 5.8% in the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock worth $213,000 after acquiring an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

ALNY has been the subject of several research analyst reports. UBS Group increased their price objective on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. HC Wainwright restated a "buy" rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research report on Friday, March 21st. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Finally, Wall Street Zen cut Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $337.91.

Alnylam Pharmaceuticals Trading Up 1.4%

NASDAQ:ALNY traded up $4.58 during mid-day trading on Friday, reaching $322.83. The company's stock had a trading volume of 2,051,645 shares, compared to its average volume of 859,177. The company's fifty day simple moving average is $286.24 and its two-hundred day simple moving average is $263.45. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $326.03. The stock has a market cap of $42.09 billion, a P/E ratio of -154.46 and a beta of 0.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same period in the previous year, the business posted ($0.16) earnings per share. The firm's quarterly revenue was up 20.2% on a year-over-year basis. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer now directly owns 48,948 shares in the company, valued at $14,978,088. This trade represents a 28.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.